Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonist albiglutide ( HARMONY 1 trial): 52‐week primary endpoint results from a randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims: To show that albiglutide, a glucagon‐like peptide‐1 receptor agonist, is an effective and generally safe treatment to improve glycaemic control in patients with type 2 diabetes mellitus whose hyperglycaemia is inadequately controlled with pioglitazone (with or without metformin). Methods: In this 3‐year, randomized, double‐blind, placebo‐controlled study, 310 adult patients on a regimen of pioglitazone (with or without metformin) were randomly assigned to receive additional treatment with albiglutide [30 mg subcutaneous (s.c.) once weekly, n = 155] or matching placebo (n = 155). The primary efficacy endpoint was change from baseline to week 52 (intention‐to‐treat) in glycated haemoglobin ( HbA1c ). Results: The model‐adjusted change from baseline in HbA1c at week 52 was significantly better with albiglutide than with placebo (−0.8%, 95% confidence interval −1.0, −0.6; p < 0.0001). Change from baseline fasting plasma glucose was −1.3 mmol/l in the albiglutide group and +0.4 mmol/l in the placebo group (p < 0.0001); a significantly higher percentage of patients reached the HbA1c goals with albiglutide (p < 0.0001), and the rate of hyperglycaemia rescue up to week 52 for albiglutide was 24.4 versus 47.7% for placebo (p < 0.0001). Albiglutide plus pioglitazone had no impact on weight, and severe hypoglycaemia was observed rarely (n = 2). With few exceptions, the results of safety assessments were similar between the groups, and most adverse events ( AEs ) were mild or moderate. The 52‐week incidence rates for gastrointestinal AEs for albiglutide and placebo were: 31.3 and 29.8%, respectively (diarrhoea: 11.3 and 8.6%; nausea: 10.7 and 11.3%; vomiting: 4.0 and 4.0%). Conclusions: Albiglutide 30 mg administered once weekly as an add‐on to pioglitazone (with or without metformin) provided effective and durable glucose lowering and was generally well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · cited 1×
“Previous results for this combination have shown it is well tolerated, provides beneficial improvements in glycaemic control and a low incidence of hypoglycaemia and does not lead to the weight gain usually associated with thiazolidinediones [3,4].”
ResultPratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326 · cited 1×
“In studies in which exenatide [17] or liraglutide [7] was included as a positive control, the incidence of GI AEs was lower in the albiglutide groups compared with the comparator GLP-1 receptor agonists.”
ResultSelf-citation
Cited by
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
“HARMONY I [60] 1041 TZD Placebo Albiglutide 30 mg: –0.”
Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321
“…consistent with those previously reported in the literature for other GLP-1RAs in combination with metformin and supported by the open-label trial arm, where reductions in HbA1c were similar (Figure S1A; Table S3) (Dungan et al., 2014; Nauck et al., 2009; Reusch et al., 2014; Wysham et al., 2014).”
ResultMechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
Latest approaches for the treatment of obesity
Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1044966 · Cited by 132
“A once weekly GLP-1R agonist, albiglutide, that is composed of a DPP4-resistant GLP-1-dimer fused to recombinant albumin failed to reduce weight in patients with T2D despite lowering HbA1c by ~ 0.9% [120,121] .”
InfluentialRosenstock, J., Nino, A., Soffer, J., Erskine, L., Acusta, A., Dole, J., Carr, M. C., Mallory, J., & Home, P. (2020) · Diabetes Care · doi:10.2337/dc19-2316 · Cited by 73
NREU, B., DICEMBRINI, I., TINTI, F., MANNUCCI, E., & MONAMI, M. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03219-8 · Cited by 63
Ebrahimi, P., Batlle, J. C., Ayati, A., Maqsood, M. H., Long, C., Tarabanis, C., McGowan, N., Liebers, D. T., Laynor, G., Hosseini, K., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0091 · Cited by 51
Albiglutide: First Global Approval
Poole, R. M., & Nowlan, M. L. (2014) · Drugs · doi:10.1007/s40265-014-0228-2 · Cited by 49
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, I., & Pérez, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0204-6 · Cited by 39
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
“[85] HARMONY-2 reported an HbA1c difference of −0.”
BackgroundHosseinpour, A., Sood, A., Kamalpour, J., Zandi, E., Pakmehr, S., Hosseinpour, H., Sood, A., Agrawal, A., & Gupta, R. (2024) · Clinical Cardiology · doi:10.1002/clc.24314 · Cited by 40
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35
“Ahrén et al, 2013* NCT00712673 20 Matching placebo 24 510 (212/298) 170 (81/89) 680 (43) C”
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
Shaddinger, B. C., Young, M. A., Billiard, J., Collins, D. A., Hussaini, A., & Nino, A. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.940 · Cited by 22
Metadata
- Authors
- Reusch, J., Stewart, M. W., Perkins, C. M., Cirkel, D. T., Ye, J., Perry, C. R., Reinhardt, R. R., & Bode, B. W.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-10-06
- Volume
- 16
- Issue
- 12
- Pages
- 1257-1264
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1945841307
- Cited by
- 110
- References
- 5
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.